Summit Therapeutics (SMMT) Equity Ratio (2019 - 2026)

Summit Therapeutics has reported Equity Ratio for 8 years, with the latest figure at 0.84 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 6.07% year-over-year to 0.84; the trailing twelve-month figure through Mar 2026 stood at 0.84 (down 6.07% YoY), and the FY2025 full-year result was 0.88, down 1.73% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.84, down from 0.88 in the prior quarter.
• The five-year high for Equity Ratio was 0.9 in Q1 2025, with the low at 0.19 in Q4 2022.
• Historically, Equity Ratio has averaged 0.63 across 5 years, with a median of 0.57 in 2024.
• Annual changes were most pronounced in 2022 — Equity Ratio sank 74.04% — and 2025, when it surged 258.72%.
• Summit Therapeutics' Equity Ratio stood at 0.19 in 2022, then soared by 100.75% to 0.38 in 2023, then jumped by 133.15% to 0.89 in 2024, then decreased by 1.73% to 0.88 in 2025, then dropped by 3.92% to 0.84 in 2026.
• The last three Equity Ratio figures came in at 0.84 (Q1 2026), 0.88 (Q4 2025), and 0.73 (Q3 2025), per Business Quant data.